-
Jerry Beeler posted an update in the group
Research and Development 3 years, 2 months ago
https://www.cbs19.tv/mobile/article/news/tyler-doctors-develop-drug-that-could-reverse-lung-scarring/501-bca22784-f9e6-4571-b14f-47d4dceb7fe4
I thought this report would be of interest.
Activity
Login
Search forums
Who’s Online
There are no users currently online
Newest Topics
Recent Replies
Members
-
Active 57 minutes ago
-
Active 1 hour ago
-
Active 1 hour, 12 minutes ago
-
Active 1 hour, 50 minutes ago
-
Active 2 hours, 34 minutes ago
Forums
- Coronavirus (COVID-19) and Pulmonary Fibrosis
- Healthy Recipe Sharing
- Hobbies & Projects
- Polls & Quizzes
- Using Our Forums
- Flash Briefings & Podcasts
- Join the Discussion: Welcome to all PF/IPF Patients
- 30 Days of PF
- In Loving Memory
- Wednesday Wins
- Diagnosis Information and General Questions
- Caregivers and Spouses
- Employment & Pulmonary Fibrosis
- Clinical Trials
- Research and Development
- Esbriet (Pirfenidone)
- Ofev (Nintedanib)
- Canadians Living with Pulmonary Fibrosis
- Pulmonary Fibrosis Awareness & Advocacy
- PF Caregivers, Family Members & Spouses
- Living with Pulmonary Fibrosis: 50+
- Pre/Post Lung Transplant
- Young Adults Living with Pulmonary Fibrosis (40 & Under)
- Upcoming Medical Appointments: Q&As
Hi @jerbeetwo,
Thank you so much for sharing this, I hadn’t seen it! I am going to post it as a forum topic for discussion (with due credit to you for sharing originally, of course) so that everyone can ensure they see it. I also want to send it to our scientific writers and researchers here at BioNews so they can keep a pulse on any follow up pertaining to this drug. Thanks again for sharing!
Charlene.
Well lucky for me I live 20 miles from this medical facility and it happened to be on our local news.
That is really lucky @jerbeetwo,
Do you think you’ll connect with that centre for participation in any trials they might have coming up pertaining to the drug showcased on the news report? I’ve heard lots of great things about UT!
Take care,
Charlene.